# L&L

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/l-l-2

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.lnlbio.com
- Latest round: Series B (Mar 20, 2023)
- Investors on record: 6

## About

Based in Shanghai, China and founded in 2015, L&L Biopharma Co., LTD., trading as L&L, is a high-tech enterprise focusing on the research and development of innovative biological macromolecule drugs. The company has applied for and has been authorized more than 30 domestic and international invention patents. It has discovery platforms for monoclonal antibodies, bispecific antibodies, and multispecific antibodies, including antibody sequence discovery platforms, computer modeling humanization technology platforms, and efficient engineering cell line platforms. In December 2025, L&L raised a series B++ funding led by new investor Renxi Fund, with participation from new investor Zhongchuang Capital and other unspecified investors. 
The company engaged in the field of biomedicine, research and development of new drugs for tumor immunotherapy, focusing on the development of first-in-class products in the field of monoclonal antibodies, bispecific antibody new drugs, and tumor immunotherapy subdivisions. The company's first core product under development, BIS5, is a dual-antibody product for the treatment of lung cancer, which aims to address the clinical needs of patients with ineffective and drug-resistant PD-1 treatment. BIS2 is a dual-target immunotherapy product for patients with pancreatic cancer and gastric cancer.
The company's revenue is generated by providing new drugs for tumor immunotherapy.
The series B++ funds will primarily be used for Phase II/III clinical trials targeting immunosuppressed cervical cancer.

## Funding rounds

- Series B, Mar 20, 2023 — Qiaojing Capital, Shenzhen Oriental Huisheng Capital Management, Hongfeng Venture, ChiNext Qianhai Capital
- Series A, May 8, 2021 — Panlin Capital, Qiaojing Capital, Topping Capital, Hongfeng Venture
- Angel, Jul 23, 2019 — Topping Capital

## Investors

- Topping Capital (https://capitalatlas.ai/funds/topping-capital) — Angel, Series A
- Panlin Capital (https://capitalatlas.ai/funds/panlin-capital) — Series A
- Qiaojing Capital (https://capitalatlas.ai/funds/qiaojing-capital) — Series A, Series B
- Hongfeng Venture (https://capitalatlas.ai/funds/hongfeng-venture) — Series A, Series B
- Shenzhen Oriental Huisheng Capital Management — Series B
- ChiNext Qianhai Capital — Series B